Consun Pharmaceutical Group Limited (HKG:1681)

Market Cap	12.51B
Revenue (ttm)	3.58B
Net Income (ttm)	1.11B
Shares Out	841.11M
EPS (ttm)	1.29
PE Ratio	11.53
Forward PE	9.70
Dividend	0.66 (4.40%)
Ex-Dividend Date	Sep 4, 2025

Volume	1,073,000
Average Volume	1,467,236
Open	15.06
Previous Close	15.00
Day's Range	14.72 - 15.11
52-Week Range	7.35 - 17.68
Beta	0.53
RSI	50.97
Earnings Date	Nov 18, 2025

About HKG:1681

Consun Pharmaceutical Group Limited researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China. It operates in two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function ass...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 3,164
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1681

Financial Performance

In 2024, HKG:1681's revenue was 2.97 billion, an increase of 14.56% compared to the previous year's 2.59 billion. Earnings were 910.46 million, an increase of 16.05%.

Financial numbers in CNY